MediciNova Number of Employees 2010-2022 | MNOV
MediciNova number of employees from 2010 to 2022. Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis
| MediciNova Annual Number of Employees |
| 2022 |
13 |
| 2021 |
11 |
| 2020 |
|
| 2019 |
8 |
| 2018 |
9 |
| 2017 |
9 |
| 2016 |
10 |
| 2015 |
10 |
| 2014 |
10 |
| 2013 |
11 |
| 2012 |
12 |
| 2011 |
|
| 2010 |
|
| 2009 |
26 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.109B |
$0.004B |
|
MEDICINOVA, INC. is a publicly-traded biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical need with a specific focus on the U.S. market. Through strategic alliances primarily with Japanesepharmaceutical companies, MediciNova holds rights to a diversified portfolio of clinical and preclinical product candidates, each of which MediciNova believes has a well-characterized and differentiated therapeutic profile, attractive commercial potential and patent assets having claims of commercially adequate scope. MediciNova's pipeline includes six clinical-stage compounds for the treatment of status asthmaticus, multiple sclerosis, asthma, interstitial cystitis, solid tumor cancers, Generalized Anxiety Disorder, preterm labor and urinary incontinence and twopreclinical-stage compounds for the treatment of thrombotic disorders. MediciNova will seek to monetize its other product candidates at key value inflection points.
|
